Everolimus Inhibits Growth of Gemcitabine‐Resistant Pancreatic Cancer Cells via Induction of Caspase‐Dependent Apoptosis and G2/M Arrest
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.25921
Abstract: Pancreatic cancer is the fourth leading cause of cancer‐related death in the United States. While Gemcitabine‐based chemotherapy is the first‐line treatment for locally advanced pancreatic cancer, its resistance is a large obstacle in the field.… read more here.
Keywords: everolimus; gemcitabine; resistant pancreatic; pancreatic cancer ... See more keywords
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
Sign Up to like & getrecommendations! Published in 2021 at "mAbs"
DOI: 10.1080/19420862.2021.1914883
Abstract: ABSTRACT Chemoresistance, particularly to gemcitabine, is a major challenge in pancreatic cancer. The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptors 2 and 3 (HER2, HER3) are expressed in many tumors, and… read more here.
Keywords: gemcitabine; resistant pancreatic; pancreatic cancer; cancer models ... See more keywords
Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Pancreatic Cancer Cells
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15092642
Abstract: Simple Summary This study investigated the antiproliferative activity of Krukovine (KV) in oxaliplatin-resistant pancreatic cancer cells and explored the mechanism of action. KV suppresses tumor progression via the downregulation of the Erk-RPS6K-TMEM139 signaling pathway in… read more here.
Keywords: cancer; cancer cells; pancreatic cancer; resistant pancreatic ... See more keywords
4-Acetylantroquinonol B enhances cell death and inhibits autophagy by downregulating the PI3K/Akt/MDR1 pathway in gemcitabine-resistant pancreatic cancer cells
Sign Up to like & getrecommendations! Published in 2022 at "Oncology Letters"
DOI: 10.3892/ol.2022.13248
Abstract: Gemcitabine (GEM) is a typical chemotherapeutic drug used to treat pancreatic cancer, but GEM resistance develops within weeks after chemotherapy. Hence, the development of a new strategy to overcome drug resistance is urgent. 4-Acetylantroquinonol B… read more here.
Keywords: pi3k akt; gem; pancreatic cancer; resistant pancreatic ... See more keywords